Enhancement of the effect of BCG vaccine against tuberculosis using DDA/TDB liposomes containing a fusion protein of HspX, PPE44, and EsxV

References

• Kastner E, Hussain MJ, Bramwell VW, et al. Correlating liposomal adjuvant characteristics to in-vivo cell-mediated immunity using a novel Mycobacterium tuberculosis fusion protein: a multivariate analysis study. J Pharm Pharmacol. 2015;67:450–463.
   PubMed Web of Science ®Google Scholar
• Zumla A, George A, Sharma V, et al. The WHO 2014 global tuberculosis report—further to go. The Lancet Global Health. 2015;3:e10–ee2.
   PubMed Web of Science ®Google Scholar
• Anderson ST, Kaforou M, Brent AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med. 2014;370:1712–1723.
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–1180.
   PubMed Web of Science ®Google Scholar
• Xin Q, Niu H, Li Z, et al. Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice. PLoS One. 2013;8:e72745. .
   PubMed Web of Science ®Google Scholar
• Black M, Trent A, Tirrell M, et al. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines. 2010;9:157–173.
   PubMed Web of Science ®Google Scholar
• Mohammed AR, Bramwell VW, Kirby DJ, et al. Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development. Eur J Pharma Biopharmaceut. 2010;76:404–412.
   PubMed Web of Science ®Google Scholar
• Andersen P. TB vaccines: progress and problems. Trends Immunol. 2001;22:160–168.
   PubMed Web of Science ®Google Scholar
• Teutschbein J, Schumann G, Möllmann U, et al. A protein linkage map of the ESAT-6 secretion system 1 (ESX-1) of Mycobacterium tuberculosis. Microbiol Res. 2009;164:253–259.
   PubMed Web of Science ®Google Scholar
• Cuccu B, Freer G, Genovesi A, et al. Identification of a human immunodominant T-cell epitope of mycobacterium tuberculosis antigen PPE44. BMC Microbiol. 2011;11:167. .
   PubMed Web of Science ®Google Scholar
• Caccamo N, Meraviglia S, La Mendola C, et al. Characterization of HLA‐DR‐and TCR‐binding residues of an immunodominant and genetically permissive peptide of the 16‐kDa protein of Mycobacterium tuberculosis. Eur J Immunol. 2004;34:2220–2229.
   PubMed Web of Science ®Google Scholar
• Marongiu L, Donini M, Toffali L, et al. ESAT-6 and HspX improve the effectiveness of BCG to induce human dendritic cells-dependent Th1 and NK cells activation. PLoS One. 2013;8:e75684. .
   PubMed Web of Science ®Google Scholar
• Bertholet S, Ireton GC, Kahn M, et al. Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol. 2008;181:7948–7957.
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug Discov Today. 2009;14:541–551.
   PubMed Web of Science ®Google Scholar
• Holten-Andersen L, Doherty T, Korsholm K, et al. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun. 2004;72:1608–1617.
   PubMed Web of Science ®Google Scholar
• Verma I, Pandey R, Khuller G. Liposomes as adjuvant for anti-mycobacterial vaccine development. 2004;42(10):949-954.
   Google Scholar
• Barratt G, Tenu J-P, Yapo A, et al. Preparation and characterisation of liposomes containing mannosylated phospholipids capable of targetting drugs to macrophages. Biochim Biophys Acta Biomembr. 1986;862:153–164.
   PubMed Web of Science ®Google Scholar
• Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb). 2004;84:93–101.
   PubMed Web of Science ®Google Scholar
• Cooper AM, Adams LB, Dalton DK, et al. IFN-gamma and NO in mycobacterial disease: new jobs for old hands. Trends Microbiol. 2002;10:221–226.
   PubMed Web of Science ®Google Scholar
• Ottenhoff TH, Verreck FA, Hoeve MA, et al. Control of human host immunity to mycobacteria. Tuberculosis (Edinb). 2005;85:53–64.
   PubMed Web of Science ®Google Scholar
• Hilgers LT, Snippe H. DDA as an immunological adjuvant. Res Immunol. 1992;143:494–503.
   PubMedGoogle Scholar
• Schoenen H, Bodendorfer B, Hitchens K, et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol. 2010;184:2756–2760.
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Hansen J, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 2008;3:e3116.
   PubMed Web of Science ®Google Scholar
• Werninghaus K, Babiak A, Gross O, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med. 2009;206:89–97.
   PubMed Web of Science ®Google Scholar
• Amini Y, Tafaghodi M, Amel Jamehdar S, et al. Heterologous expression, purification, and characterization of the HspX, Ppe44, and EsxV proteins of Mycobacterium tuberculosis. Rep Biochem Molecular Biol. 2018;6:125–130.
   PubMed Web of Science ®Google Scholar
• Feitosa E, Barreleiro P, Olofsson G. Phase transition in dioctadecyldimethylammonium bromide and chloride vesicles prepared by different methods. Chem Phys Lipids. 2000;105:201–213.
   PubMed Web of Science ®Google Scholar
• Hojatizade M, Badiee A, Khamesipour A, et al. DDA/TDB liposomes containing soluble Leishmania major antigens induced a mixed Th1/Th2 immune response in BALB/c mice. Nanomed J. 2017;4:71–82.
   Google Scholar
• Andersen P, Doherty TM. Opinion: The success and failure of BCG–implications for a novel tuberculosis vaccine. Nat Rev Micro. 2005;3:656.
   PubMed Web of Science ®Google Scholar
• Yuan X, Teng X, Jing Y, et al. A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection. Appl Microbiol Biotechnol. 2015;99:10587–10595.
   PubMed Web of Science ®Google Scholar
• Niu H, Peng J, Bai C, et al. Multi-stage tuberculosis subunit vaccine candidate LT69 provides high protection against Mycobacterium tuberculosis infection in mice. PLoS One. 2015;10:e0130641.
   PubMed Web of Science ®Google Scholar
• Knudsen NPH, Nørskov-Lauritsen S, Dolganov GM, et al. Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc Natl Acad Sci. 2014;111:1096–1101.
   PubMed Web of Science ®Google Scholar
• Romano M, Rindi L, Korf H, et al. Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c). Vaccine 2008;26:6053–6063.
   PubMed Web of Science ®Google Scholar
• Pepponi I, Diogo GR, Stylianou E, et al. Plant‐derived recombinant immune complexes as self‐adjuvanting TB immunogens for mucosal boosting of BCG. Plant Biotechnol J. 2014;12:840–850.
   PubMed Web of Science ®Google Scholar
• Yousef Amini MT, Saeid AJ, Zahra M, et al. Heterologous expression, purification, and characterization of the HspX, Ppe44, and EsxV proteins of Mycobacterium tuberculosis. Rep Biochem Molecular Biol. 2017;6(2):125-130.
   Web of Science ®Google Scholar
• Gregoriadis G. Immunological adjuvants: a role for liposomes. Immunol Today. 1990;11:89–97.
   PubMedGoogle Scholar
• Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Brazilian J Med Biol Res. 1999;32(2):181-189.
   Web of Science ®Google Scholar
• Jaafari MR, Badiee A, Khamesipour A, et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine. 2007;25:6107–6117.
   PubMed Web of Science ®Google Scholar
• Badiee A, Jaafari MR, Samiei A, et al. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol. 2008;15:668–674.
   PubMed Web of Science ®Google Scholar
• Larrouy-Maumus G, Layre E, Clark S, et al. Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis. Vaccine. 2017;35:1395–1402.
   PubMed Web of Science ®Google Scholar
• Davidsen J, Rosenkrands I, Christensen D, et al. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6, 6′-dibehenate)—a novel adjuvant inducing both strong CMI and antibody responses. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2005;1718:22–31.
   PubMed Web of Science ®Google Scholar
• Shuttleworth SJ, Allin PM, Sharma K. Functionalised polymers: recent developments and new applications in synthetic organic chemistry. Synthesis. 1997;1997:1217–1239.
   Google Scholar
• Firouzmand H, Badiee A, Khamesipour A, et al. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA). Acta Tropica. 2013;128:528–535.
   PubMed Web of Science ®Google Scholar
• Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA: TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J Control Release. 2011;154:131–137.
   PubMed Web of Science ®Google Scholar
• Kaur R, Henriksen-Lacey M, Wilkhu J, et al. Effect of incorporating cholesterol into DDA: TDB liposomal adjuvants on bilayer properties, biodistribution, and immune responses. Mol Pharmaceutics. 2014;11:197–207.
   PubMed Web of Science ®Google Scholar
• Bhatt K, Salgame P. Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol. 2007;27:347–362.
   PubMed Web of Science ®Google Scholar
• Seiler P, Aichele P, Bandermann S, et al. Early granuloma formation after aerosol Mycobacterium tuberculosis infection is regulated by neutrophils via CXCR3‐signaling chemokines. Eur J Immunol. 2003;33:2676–2686.
   PubMed Web of Science ®Google Scholar
• Khader SA, Pearl JE, Sakamoto K, et al. IL-23 compensates for the absence of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and antigen-specific IFN-gamma responses if IL-12p70 is available. J Immunol. 2005;175:788–795.
   PubMed Web of Science ®Google Scholar
• Yoshida YO, Umemura M, Yahagi A, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol. 2010;184:4414–4422.
   PubMed Web of Science ®Google Scholar
• Becattini S, Latorre D, Mele F, et al. T cell immunity. Functional heterogeneity of human memory CD4 T cell clones primed by pathogens or vaccines. Science. 2015;347:400–406.
   PubMed Web of Science ®Google Scholar
• Khader SA, Bell GK, Pearl JE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8:369.
   PubMed Web of Science ®Google Scholar
• Rook GA, Hernandez-Pando R, Dheda K, et al. IL-4 in tuberculosis: implications for vaccine design. Trends in Immunol. 2004;25:83–88.
   Web of Science ®Google Scholar
• Demissie A, Abebe M, Aseffa A, et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL. J Immunol. 2004;172:6938–6943. 4δ2.
   PubMed Web of Science ®Google Scholar
• Ordway DJ, Costa L, Martins M, et al. Increased Interleukin-4 Production by CD8 and gammadelta T cells in health-care workers is associated with the subsequent development of active tuberculosis. J Infect Dis. 2004;190:756–766.
   PubMed Web of Science ®Google Scholar
• Kara EE, Comerford I, Fenix KA, et al. Tailored immune responses: novel effector helper T cell subsets in protective immunity. PLoS Pathog. 2014;10:e1003905.
   PubMed Web of Science ®Google Scholar
• Jacobs AJ, Mongkolsapaya J, Screaton GR, et al. Antibodies and tuberculosis. Tuberculosis (Edinb). 2016;101:102–113.
   PubMed Web of Science ®Google Scholar
• Brandt L, Skeiky YA, Alderson MR, et al. The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun. 2004;72:6622–6632.
   PubMed Web of Science ®Google Scholar
• Goonetilleke NP, McShane H, Hannan CM, et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol. 2003;171:1602–1609.
   PubMed Web of Science ®Google Scholar